Last updated: April 15, 2026
What is NDC 76204-0028?
NDC 76204-0028 refers to a specific pharmaceutical product approved by the U.S. Food and Drug Administration (FDA). The product is Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy designed to treat spinal muscular atrophy (SMA) in pediatric patients.
Market Overview
Current Market Landscape
Zolgensma holds a dominant position in the gene therapy market for SMA. The drug addresses a rare but severe neuromuscular disorder prevalent in infants and young children. The global SMA treatment market has experienced growth driven by increased diagnosis, approved novel therapies, and broader insurer coverage.
Competitors
- Spinraza (nusinersen): Biogen’s antisense oligonucleotide, approved in 2016.
- Evrysdi (risdiplam): Roche's oral treatment approved in 2020.
- Other developmental gene therapies: Under clinical investigation, but none with comparable approval status as Zolgensma.
Market Size and Growth
- The global SMA market was valued at approximately USD 600 million in 2022.
- Compound annual growth rate (CAGR) projected between 12-15% through 2027 (Market Research Future, 2022).
Key Drivers
- Increasing newborn screening programs.
- Growing awareness among healthcare providers and patients.
- Innovation in gene therapy enabling broader access.
Pricing Structure and Developmental Economics
Current Price Point
- List Price: Approximate upfront cost of Zolgensma is USD 2.125 million per dose.
- Pricing Model: Single-dose infusion; costs are often offset via payer negotiations and patient assistance programs.
Cost Components
- Manufacturing: High due to complex vector production processes.
- R&D: Substantial, with investments exceeding USD 1 billion since development initiation.
- Distribution: Cold chain logistics, specialized healthcare provider administration.
Reimbursement Strategies
Payors often negotiate installment or outcome-based payments, given the high upfront cost. Some agreements include pay-for-performance schemes based on clinical outcomes, influencing net pricing.
Market Penetration and Adoption
- As of 2023, over 1,200 patients globally have received Zolgensma.
- Market penetration remains limited in developing regions due to cost and healthcare infrastructure.
Price Projections
Short-term Outlook (2023-2025)
- Stable Pricing: Given the high value and demand, list prices are unlikely to decrease significantly.
- Potential Modifiers: Expansion of approved indications, such as late-onset SMA, could slightly increase overall revenue.
Mid to Long-term Outlook (2026-2030)
- Price erosion risk: Competitive gene therapies entering the market could pressure prices downward.
- Market expansion: Entry into emerging markets may drive volume but at discounted prices to accommodate local economic conditions.
- Manufacturing improvements: Cost reductions in vector production could lower net costs, positively influencing pricing strategies.
Estimated Revenue Projections
Assuming steady demand and no major policy shifts:
- Yearly sales could approach USD 2 billion globally by 2026.
- Price per dose will likely hover around the current USD 2.1 million, with potential for slight reductions based on market competition and payer negotiations.
Policy and Regulatory Impact
Recent FDA alignment on reimbursement models and global health initiatives could influence future pricing. States with expanded newborn screening programs can facilitate early diagnosis, increasing treatment volume and impact on price per patient.
Key Takeaways
- NDC 76204-0028 (Zolgensma) currently commands a high list price of approximately USD 2.125 million per dose.
- The market is characterized by high barriers, including manufacturing costs, regulatory approval, and payer negotiations.
- Growing patient numbers, especially through newborn screening, could sustain or slightly increase revenues over the next three to five years.
- Price competition from emerging gene therapies and biosimilars remains a risk, potentially leading to price erosion starting around 2026.
- Expansion into new indications and markets is expected to drive sales growth, although at potentially lower net prices.
FAQs
1. What factors influence the pricing of Zolgensma?
Manufacturing complexity, R&D investment, market demand, reimbursement negotiations, and competition influence pricing.
2. How does payer negotiation impact the net price?
Insurers often negotiate installment plans or outcome-based payments, reducing financial risk and influencing net revenue.
3. When might price erosion occur?
Price reductions could begin with increased competition or new biosimilars entering the market, likely post-2025.
4. Are there approved indications other than SMA in infants?
As of 2023, Zolgensma is primarily approved for infants and pediatric patients under two years with SMA.
5. What opportunities exist for expanding market share?
Expanded indications, broader global access, and government-led screening programs can increase treatment volume.
Sources
[1] Market Research Future. (2022). Global SMA Market.
[2] FDA. (2020). Zolgensma approval information.
[3] IQVIA. (2023). U.S. pharmaceutical pricing and reimbursement report.
[4] Bernstein, J. (2022). Gene therapy market trends. Gen Therapy Insights.
[5] Institute for Clinical and Economic Review. (2022). SMA therapies cost-effectiveness analyses.
